Professor Thomas Ebenhan started a postdoctoral project in infection imaging in 2010. His scientific education was done in biochemistry at the University of Tubingen, Germany, with a focus on pharmacology and toxicology. During his postgraduate education, he became involved in the field of radiopharmacology and nuclear medicine. From 2005 to 2009, he was working as a researcher for the Novartis Pharma AG (Global Imaging Group) in collaboration with the Federal University of Zurich. He is an NRF-C1-rated scientist and an Associate Professor at the University of Pretoria. He currently investigates radiolabeled antimicrobial peptides as infection imaging agents and develops suitable animal models to target tuberculosis.